Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 947 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas
Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia . Can Med Assoc J 2017;189:E517-518. [Ref.ID 101525]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S. Risk of pneumonia associated with incident benzodiazepine use among community- dwelling adults with Alzheimer disease. Can Med Assoc J 2017;189:E519-529. [Ref.ID 101524]
3. Cita con resumen
Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:1. [Ref.ID 100993]
6. Cita con resumen
Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]
8.
Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet 2016;388:505-17. [Ref.ID 100647]
9. Cita con resumen
Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]
11.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
12.Enlace a cita original Cita con resumen
Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, Lopez OL, Mahoney J, Pasic J, Tan ZS, Wills CD, Rhoads R, Yager J. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry 2016;173:543-6. [Ref.ID 100329]
13.Tiene citas relacionadas Cita con resumen
Kuller LH. Do proton pump inhibitors increase the risk of dementia?. JAMA Neurology 2016;73:379-81. [Ref.ID 100322]
14. Cita con resumen
Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack Jr CR, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ, for the Alzheimer's Disease Neuroimaging Initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurology 2016;73:721-32. [Ref.ID 100315]
15.Tiene citas relacionadas Cita con resumen
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology 2016;73:410-6. [Ref.ID 100299]
16. Cita con resumen
Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016;374:523-32. [Ref.ID 100130]
17. Cita con resumen
Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, Crane PK, Larson EB. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ 2016;352:i90. [Ref.ID 100037]
18. Cita con resumen
Anónimo. Donepezilo y riesgo de rabdomiólisis y de síndrome neuroléptico maligno. Butlletí de Farmacovigilància de Catalunya 2015;13:19. [Ref.ID 99837]
19.Tiene citas relacionadas Cita con resumen
O'Brien JT, Thomas A. Vascular dementia. Lancet 2015;386:1698-706. [Ref.ID 99820]
20.Tiene citas relacionadas Cita con resumen
Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386:1683-97. [Ref.ID 99819]
Seleccionar todas
 
 1 a 20 de 947 siguiente >>